NCT04732650View on ClinicalTrials.gov

Real World Difference After Changing Medication From Nonselective to Selective Endothelin Receptor Antagonist in Stable Eisenmenger Syndrome

UnknownOBSERVATIONAL

Enrollment

40

Participants

Timeline

Start Date

February 4, 2021

Primary Completion Date

December 31, 2023

Study Completion Date

December 31, 2024

Conditions

Eisenmenger Complex

Sponsors

Collaborators (1)

GlaxoSmithKline

All Listed Sponsors

collaborator

GlaxoSmithKline

INDUSTRY

lead

Samsung Medical Center

OTHER

NCT04732650 - Real World Difference After Changing Medication From Nonselective to Selective Endothelin Receptor Antagonist in Stable Eisenmenger Syndrome | Biotech Hunter | Biotech Hunter